Risankizumab + Placebo for risankizumab

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hidradenitis Suppurativa

Conditions

Hidradenitis Suppurativa

Trial Timeline

Jun 3, 2019 → Aug 2, 2021

NCT ID

NCT03926169

About Risankizumab + Placebo for risankizumab

Risankizumab + Placebo for risankizumab is a phase 2 stage product being developed by AbbVie for Hidradenitis Suppurativa. The current trial status is completed. This product is registered under clinical trial identifier NCT03926169. Target conditions include Hidradenitis Suppurativa.

What happened to similar drugs?

1 of 20 similar drugs in Hidradenitis Suppurativa were approved

Approved (1) Terminated (0) Active (19)

✅Placebo + AdalimumabAbbVieApproved

🔄SonelokimabMoonLake ImmunotherapeuticsPhase 3

🔄Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3

🔄Lutikizumab + PlaceboAbbViePhase 3

🔄Upadacitinib + PlaceboAbbViePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05969223	Approved	Completed	Aug 10, 2023	Nov 28, 2025	Genital Psoriasis
NCT03926169	Phase 2	Completed	Jun 3, 2019	Aug 2, 2021	Hidradenitis Suppurativa
NCT03398135	Phase 3	Active	Aug 28, 2018	Feb 1, 2029	Ulcerative Colitis (UC)
NCT03000075	Phase 2	Completed	Dec 2, 2016	Jun 20, 2018	Psoriasis
NCT02719171	Phase 2	Completed	Apr 1, 2016	Aug 1, 2017	Arthritis, Psoriatic

Competing Products

20 competing products in Hidradenitis Suppurativa

See all competitors

Product	Company	Stage	Hype Score
Sonelokimab	MoonLake Immunotherapeutics	Phase 3	41
Sonelokimab	MoonLake Immunotherapeutics	Phase 3	41
Sonelokimab + Placebo	MoonLake Immunotherapeutics	Phase 3	38
Sonelokimab + Placebo	MoonLake Immunotherapeutics	Phase 3	38
Sonelokimab (M1095) + Adalimumab	MoonLake Immunotherapeutics	Phase 2	29
Eltrekibart + Placebo	Eli Lilly	Phase 2	39
Placebo + LY3041658	Eli Lilly	Phase 2	35
Placebo + Adalimumab	AbbVie	Approved	43
Lutikizumab + Placebo	AbbVie	Phase 3	47
Adalimumab	AbbVie	Pre-clinical	26
Upadacitinib + Placebo	AbbVie	Phase 3	47
adalimumab + placebo	AbbVie	Phase 3	40
Lutikizumab	AbbVie	Phase 2	42
adalimumab	AbbVie	Phase 3	40
Lutikizumab + Placebo	AbbVie	Phase 2	39
adalimumab	AbbVie	Phase 3	40
adalimumab + placebo	AbbVie	Phase 3	40
Upadacitinib + Placebo	AbbVie	Phase 2	35
MEDI8968 + Saline	AstraZeneca	Phase 2	27
Anifrolumab	AstraZeneca	Phase 2	39